CN106267106A - 增进记忆改善老年痴呆症患者大脑健康状况的组合物 - Google Patents
增进记忆改善老年痴呆症患者大脑健康状况的组合物 Download PDFInfo
- Publication number
- CN106267106A CN106267106A CN201610850448.1A CN201610850448A CN106267106A CN 106267106 A CN106267106 A CN 106267106A CN 201610850448 A CN201610850448 A CN 201610850448A CN 106267106 A CN106267106 A CN 106267106A
- Authority
- CN
- China
- Prior art keywords
- senile dementia
- brain
- compositions
- health status
- memory improvement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 24
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000006993 memory improvement Effects 0.000 title claims abstract description 12
- 230000036995 brain health Effects 0.000 title claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 abstract description 23
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract description 13
- 210000004556 brain Anatomy 0.000 abstract description 10
- 235000016709 nutrition Nutrition 0.000 abstract description 8
- 230000035764 nutrition Effects 0.000 abstract description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 8
- 235000013824 polyphenols Nutrition 0.000 abstract description 8
- 244000194101 Ginkgo biloba Species 0.000 abstract description 7
- 244000269722 Thea sinensis Species 0.000 abstract description 7
- 229930182494 ginsenoside Natural products 0.000 abstract description 7
- 229940089161 ginsenoside Drugs 0.000 abstract description 7
- 235000011201 Ginkgo Nutrition 0.000 abstract description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 abstract description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 6
- 230000002490 cerebral effect Effects 0.000 abstract description 6
- 229910052711 selenium Inorganic materials 0.000 abstract description 6
- 239000011669 selenium Substances 0.000 abstract description 6
- 229960003080 taurine Drugs 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract description 4
- 210000002569 neuron Anatomy 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 abstract description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract description 3
- 235000009582 asparagine Nutrition 0.000 abstract description 3
- 229960001230 asparagine Drugs 0.000 abstract description 3
- 230000005540 biological transmission Effects 0.000 abstract description 3
- 235000004554 glutamine Nutrition 0.000 abstract description 3
- 239000008347 soybean phospholipid Substances 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 210000004720 cerebrum Anatomy 0.000 abstract description 2
- 230000008859 change Effects 0.000 abstract description 2
- 210000003792 cranial nerve Anatomy 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 235000003715 nutritional status Nutrition 0.000 abstract description 2
- 230000000050 nutritive effect Effects 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 2
- 239000002131 composite material Substances 0.000 abstract 2
- 229920002472 Starch Polymers 0.000 abstract 1
- 229940114079 arachidonic acid Drugs 0.000 abstract 1
- 235000021342 arachidonic acid Nutrition 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- -1 Cysteine sulfurous acid carboxylic acid Chemical class 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000024806 Brain atrophy Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000002467 anti-pepsin effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000005985 stomach dysfunction Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- NNMALANKTSRILL-ZUTFDUMMSA-N 3-[(2z,5z)-2-[[3-(2-carboxyethyl)-5-[(z)-[(3z,4r)-3-ethylidene-4-methyl-5-oxopyrrolidin-2-ylidene]methyl]-4-methyl-1h-pyrrol-2-yl]methylidene]-5-[(4-ethyl-3-methyl-5-oxopyrrol-2-yl)methylidene]-4-methylpyrrol-3-yl]propanoic acid Chemical compound O=C1C(CC)=C(C)C(\C=C/2C(=C(CCC(O)=O)C(=C/C3=C(C(C)=C(\C=C/4\C(\[C@@H](C)C(=O)N\4)=C/C)N3)CCC(O)=O)/N\2)C)=N1 NNMALANKTSRILL-ZUTFDUMMSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- INPDFIMLLXXDOQ-UHFFFAOYSA-N Phycocyanobilin Natural products CCC1=C(C)C(=CC2=NC(=C/c3[nH]c(C=C/4C(C(C(N4)=O)C)=CC)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O INPDFIMLLXXDOQ-UHFFFAOYSA-N 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Chemical class 0.000 description 1
- 239000004410 anthocyanin Chemical class 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 108010072011 phycocyanobilin Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种增进记忆改善老年痴呆症患者大脑健康状况的组合物。为治疗老年痴呆症而发明。包括：DHA藻油复合粉、谷氨酰胺、天门冬酰胺、大豆磷脂、牛磺酸、人参皂甙、银杏叶提取物、花生四烯酸油脂复合粉、茶多酚、生姜、富硒酵母、淀粉。上述的本发明组方从营养学角度出发，根据人体大脑的生理特点，从提高和改善大脑神经元细胞的营养状态及活性、提高和改善大脑血液营养传输的新陈代谢系统着手，通过极具针对性的脑神经结构的营养代谢的强化和调节，补充因衰老或多种变化引起的脑神经元主结构。克服了某些化学药物、某些中药组方产生的毒副作用及可能的不良后果，避免了医疗的非营养康复持久性差的缺陷，减少了复发的频度。
Description
技术领域
本发明涉及一种增进记忆改善老年痴呆症患者大脑健康状况的组合物。
背景技术
随着物质文明的发达，人们的生活水平越来越高，寿命也越来越长，老龄化已成为活生生的现实。伴随而来的老年性疾病，尤其是老年痴呆不仅成为老龄人个人的不幸，也成为家庭的负担、社会的累赘。在发达国家，老年痴呆已成为第四位死亡原因，在我国，由于老龄化进程的加快，老年痴呆患病率迅速上升，尤其是65岁以上患病率已接近发达国家水平。
老年痴呆是指脑组织本身没有发生器质性病变而产生萎缩的一类神经精神性疾病老年痴呆。老年痴呆属中医“痴呆”“健忘”“眩晕”“痿证”“震颤”等范畴，中医认为本病虽病位在脑但与各脏腑功能密切相关病理机制属本虚标实。最主任主要的致病因素是，脑血管长期慢性缺血而造成的。随着现代医学的不断发展，出现了一些药品，虽解除了许多患者的疾患，但多数临床医生及患者仍感到见效慢、疗效差、服药时间长、费用高、治疗面单一，与该病相关的体症不能兼顾治疗。
老年痴呆症是一种神经退行性疾病，其症状主要表现为患者记忆力和认知能力不同程度的丧失，行为活动发生障碍。研究者发现，患者脑细胞产生的神经递质有许多缺损，其中乙酰胆碱能系统神经递质缺损非常明显。老年痴呆症的致病因素有很多，但是归根结底都与神经毒素和脑衰老物质的渐进性蓄积密切相关，当神经毒素和脑衰老物质的蓄积达到一定程度时，会使脑细胞死亡的速度加快，当脑细胞死亡的数量达到人脑总量的百分之十以上时就会表现出脑萎缩的症状，当脑萎缩继续发展而不能够得到控制，就会发展到老年痴呆症的程度。目前治疗老年痴呆症的药物一般都使用乙酰胆碱前体物、卵磷脂、三弗拉嗪和T588。乙酰胆碱前体物、卵磷脂疗效轻微，副作用明显。T588属于化学药物，其副作用也非常明显。而另一类神经肽及其类是药物的临床试验结果也不佳，仅有改善患者情绪的作用。临床治疗中还使用的另一种药物是脑血管扩张药物，如长春胺等，它只适合部分轻微患者，而且有副作用。综上所述，目前国内仍然没有能够有效治疗老年痴呆症的药物。
发明内容
为克服上述缺陷，本发明提供一种治疗效果好，见效快，费用低，无任何副作用的增进记忆改善老年痴呆症患者大脑健康状况的组合物。
为达到上述目的，本发明增进记忆改善老年痴呆症患者大脑健康状况的组合物，所述的组合物由下述重量份的原料制成；
为达到上述目的，本发明增进记忆改善老年痴呆症患者大脑健康状况的组合物，所述的组合物由下述重量份的原料制成；
为达到上述目的，本发明增进记忆改善老年痴呆症患者大脑健康状况的组合物，所述的组合物由下述重量份的原料制成；
上述本发明的原料中，
谷氨酰胺，
学名2-氨基-4-氨甲酰基丁酸，英文Glutamine(Gln)。是谷氨酸的酰胺。L-谷氨酰胺是蛋白质合成中的编码氨基酸，哺乳动物非必需氨基酸，在体内可以由葡萄糖转变而来。具有重要的免疫调节作用，它是淋巴细胞分泌、增殖及其功能维持所必需的。改善脑机能。提高机体的抗氧化能力。促进大脑发育，增强记忆。
天门冬酰胺
天门冬酰胺是一种药物，适用症状为降血压，扩张支气管(平喘),抗消化性溃疡及胃功能障碍。降血压,扩张支气管(平喘),抗消化性溃疡及胃功能障碍。
大豆磷脂，磷脂是从生产大豆油的油脚中提取的产物，是由甘油、脂肪酸、胆碱或胆胺所组成的酯，能溶于油脂及非极性溶剂。大豆磷脂的组成成分复杂，主要含有卵磷脂(约34.2％)、脑磷脂(约19.7％)、肌醇磷脂(约16.0％)、磷酯酰丝氨酸(约15.8％)、磷脂酸(约3.6％)及其他磷脂(约10.7％)。为浅黄至棕色的黏稠液体或白色至浅棕色的固体粉末。
牛磺酸
又称β-氨基乙磺酸，最早由牛黄中分离出来，故得名。纯品为无色或白色斜状晶体，无臭，牛磺酸化学性质稳定，不溶于乙醚等有机溶剂，是一种含硫的非蛋白氨基酸，在体内以游离状态存在，不参与体内蛋白的生物合成。牛磺酸虽然不参与蛋白质合成，但它却与胱氨酸、半胱氨酸的代谢密切相关。人体合成牛磺酸的半胱氨酸亚硫酸羧酶(CSAD)活性较低，主要依靠摄取食物中的牛磺酸来满足机体需要。
人参皂苷
人参皂苷(Ginsenoside)是一种固醇类化合物，三萜皂苷。主要存在于人参属药材中。人参皂苷被视为是人参中的活性成分，因而成为研究的目标。因为人参皂苷影响了多重的代谢通路，所以其效能也是复杂的，而且各种人参皂苷的单体成分是难以分离出来的。
银杏提取物(银杏叶提取物)，银杏科植物银杏Ginkgo biloba L.的干燥叶提取物，为浅黄棕色可流动性粉末，味苦，具有活血、化瘀、通络的功效。银杏叶目前仍被中国医药用于治疗记忆丢失，胃部疼痛，痢疾，高血压、精神紧张和呼吸道问题如哮喘，支气管炎和循环不良及其引起的焦虑。银杏的活性成分是萜烯部分，其中包括银杏内酯和白果内酯。这些银杏黄酮－糖甙成分具有强大的抗氧化与清除自由基能力。
银杏叶提取物的药用价值与应用极为广泛。采用先进的技术、工艺和设备，通过进一步提取、分离和纯化，其药理作用更加明显，除具有显著的拮抗PAF受体外，还可以在抗炎、抗过敏、扩张血管、保护心脑血管、改善外周血液循环、降低血清胆固醇及辅助抗癌等方面发挥药效，可以广泛应用于心脑血管、神经等系统疾病的防治和保健。
茶多酚，
茶多酚是茶叶中多酚类物质的总称，包括黄烷醇类、花色苷类、黄酮类、黄酮醇类和酚酸类等。主要为黄烷醇(儿茶素)类，儿茶素占60～80％。类物质茶多酚又称茶鞣或茶单宁，是形成茶叶色香味的主要成份之一，也是茶叶中有保健功能的主要成份之一。研究表明，茶多酚等活性物质具解毒和抗辐射作用，能有效地阻止放射性物质侵入骨髓，并可使锶90和钴60迅速排出体外，被健康及医学界誉为“辐射克星”。具有抗脂质过氧化，预防衰老等效果。并且，茶多酚还有清除自由基的作用，可抑制皮肤线粒体中脂氧合酶和脂质过氧化作用，从而具有抗衰老效应。研究表明，茶多酚的抗氧性明显优于维生素E，且与维生素C、E有增效效应。通过调节免疫球蛋白的活性，间接实现提高人体综合免疫能力、抗风湿因子、抗菌抗病毒的功效。
富硒酵母
富硒酵母有很好的日出基清除功能，抑制细胞膜的脂质过氧化及提高机体免疫功能，从而延缓组织细胞的衰老进程，表现出明显的抗衰老作用，可作为抗衰老食品的活性成分。其中，硒是人体所必需的微量元素，有很重要的生理功能，与人类的健康密切相关。硒能够预防和抑制肿瘤、抗衰老、维持心血管系统的正常功能，预防动脉硬化和冠心病的出现。缺硒会导致克山病和大骨结病，还会诱发白内障、肝病和胰腺病等等。酵母是人类利用最广的微生物，其蛋白质含量高达50％以上，还含有丰富的B族维生素和多种矿物质，被称为优质营养之源。
藻蓝蛋白
是从螺旋藻中分离出的一种深蓝色粉末。主要存在于蓝藻、红藻和隐藻中。藻蓝素通常也分为C-藻蓝素和R-藻蓝素，前者主要存在于蓝藻中，后者则主要存在于红藻中，隐藻中该两种都有。其功用为吸收光(橙黄色)能和传递光能[1]。它既是一种蛋白质，又是一种极好的天然食用色素，同时又是良好的保健食品。
上述的本发明组方从营养学角度出发，根据人体大脑的生理特点，从提高和改善大脑神经元细胞的营养状态及活性、提高和改善大脑血液营养传输的新陈代谢系统着手，通过极具针对性的脑神经结构的营养代谢的强化和调节，补充因衰老或多种变化引起的脑神经元主结构：轴突和树突内部物质组成的隐性缺失而致的神经休眠或坏死等病变。利用营养物质本身特性多靶点、多途径对大脑进行深层次多级立体复合的营养代谢调理，从而修复、微调与重构病患大脑神经系统，使轴突粗大，树突分叉多枝，信息传递加快。克服了某些化学药物、某些中药组方产生的毒副作用及可能的不良后果，避免了医疗的非营养康复持久性差的缺陷，减少了复发的频度。
具体实施方式
实施例1
上述的原料制成胶囊，每料0.25-0.35克，每日三次，视情况每次3-8粒。
实施例2
上述的原料制成胶囊，每料0.25-0.35克，每日三次，视情况每次3-8粒。每个疗程30天。
实施例3
上述本发明的实施例，对增进记忆改善老年痴呆症非常有效，经临床使用200余例，有效率达100％。
以下随即选了几个病案的治疗记录：
李XX，女，80岁，2010年6月间患痴呆症，发病后，亲属全都不认识了，卧床不能起来，生活不能自理，2015年2月开始服用本药。服用一个疗程后，病情有了很大好转，能下床走路，认识亲人了，后为又续服了本药至今，生活智力基本恢复。
金XX，男，88岁，2010年该老人患糖尿病综合症，有严重的痴呆行为，不能下地走路，眼光呆滞2014年10月开始服用本药一个疗程后眼晴就灵活了，并能下地走路了。
英X，男，70多岁，一次意外导致失去记忆，一分钟的事都记不住，使家人很烦。服用本药一个疗程后，记忆有明显改善。至今仍继续服用。
张XX女，85岁，患有痴呆症，嘴合不拢，舌尖在嘴边打抖。2016年初开始服用本发药，两个疗程后，嘴能合扰，舌尖不抖了，精神也好多了。
刘XX 91岁，患痴呆症。2016年服用本药1个疗程后初见成效，至今仍在服用，效果明显。
从本发明中药治疗的病人状况来看，疗效非常好，能完全治好老年人的痴呆症。
本发明具有主线条清晰，多层次、交叉性、多靶点为特点进行的食疗强化与调整调理，疗效显著有效，兼具中西药疗法与营养调整的多重机理交叉复合优势。因其具有多重机理相协同配合的理论基础，良性增强放大作用显著，因而食疗效果显著。适用于记忆力减退、神经衰弱、帕金森综合征前期症状、老年痴呆伴餐维护、部分脑供血不足等因代谢而致的心脑血管疾病的患者维持维护康复保健营养调理调整。经临床200余例证实，是一种优良确切的食疗补剂组方，是当代广大老年脑疾患者及神经记忆门诊患者的福音。
Claims (3)
1.一种用于增进记忆改善老年痴呆症患者大脑健康状况的组合物，其特征在于，由下述重量份的原料组成：
2.一种用于增进记忆改善老年痴呆症患者大脑健康状况的组合物，其特征在于，由下述重量份的原料组成：
3.一种用于增进记忆改善老年痴呆症患者大脑健康状况的组合物，其特征在于，由下述重量份的原料组成：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610850448.1A CN106267106A (zh) | 2016-09-26 | 2016-09-26 | 增进记忆改善老年痴呆症患者大脑健康状况的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610850448.1A CN106267106A (zh) | 2016-09-26 | 2016-09-26 | 增进记忆改善老年痴呆症患者大脑健康状况的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106267106A true CN106267106A (zh) | 2017-01-04 |
Family
ID=57715027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610850448.1A Pending CN106267106A (zh) | 2016-09-26 | 2016-09-26 | 增进记忆改善老年痴呆症患者大脑健康状况的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106267106A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109091484A (zh) * | 2018-08-15 | 2018-12-28 | 湖南恒伟药业股份有限公司 | 一种预防和治疗阿尔兹海默症的药物组合物 |
| CN109106738A (zh) * | 2018-09-12 | 2019-01-01 | 沈阳高名医药科技有限公司 | 一种神经酸组合物及其在神经保护中的应用 |
| CN111248439A (zh) * | 2020-03-31 | 2020-06-09 | 唯思敦食品(上海)有限公司 | 一种预防和辅助治疗阿尔茨海默症的保健食品及其制备方法 |
| CN112753765A (zh) * | 2019-11-04 | 2021-05-07 | 内蒙古蒙牛乳业（集团）股份有限公司 | 一种抗氧化剂、抗氧化酸奶及其制备方法 |
| CN114287626A (zh) * | 2022-01-12 | 2022-04-08 | 唯思敦食品(上海)有限公司 | 一种健脑组合物及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101253990A (zh) * | 2008-04-09 | 2008-09-03 | 北京市科威华食品工程技术有限公司 | 一种改善记忆功能软胶囊 |
| CN102526316A (zh) * | 2012-01-18 | 2012-07-04 | 张树球 | 一种防治老年痴呆症的中药制剂及其生产方法 |
| CN102793185A (zh) * | 2012-07-20 | 2012-11-28 | 惠州市鑫福来实业发展有限公司 | 一种辅助改善记忆力的麦瑞片及其制备方法 |
| CN103690581A (zh) * | 2013-12-22 | 2014-04-02 | 王雪雁 | 一种治疗老年痴呆症的药物组合物 |
-
2016
- 2016-09-26 CN CN201610850448.1A patent/CN106267106A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101253990A (zh) * | 2008-04-09 | 2008-09-03 | 北京市科威华食品工程技术有限公司 | 一种改善记忆功能软胶囊 |
| CN102526316A (zh) * | 2012-01-18 | 2012-07-04 | 张树球 | 一种防治老年痴呆症的中药制剂及其生产方法 |
| CN102793185A (zh) * | 2012-07-20 | 2012-11-28 | 惠州市鑫福来实业发展有限公司 | 一种辅助改善记忆力的麦瑞片及其制备方法 |
| CN103690581A (zh) * | 2013-12-22 | 2014-04-02 | 王雪雁 | 一种治疗老年痴呆症的药物组合物 |
Non-Patent Citations (3)
| Title |
|---|
| 丁慧萍，等: ""藻油及鱼油二十二碳六烯酸复方制剂对儿童记忆功能的影响"", 《中国营养学会第十一次全国营养科学大会暨国际DRIS研讨会学术报告及论文摘要汇编（上册）——DRIS新进展：循证营养科学与实践学术》 * |
| 徐维盛，等: ""DHA藻油软胶囊改善小鼠记忆功能的研究"", 《卫生研究》 * |
| 陈鹏，等: ""国内辅助改善记忆功能性食品研究进展"", 《中国食品学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109091484A (zh) * | 2018-08-15 | 2018-12-28 | 湖南恒伟药业股份有限公司 | 一种预防和治疗阿尔兹海默症的药物组合物 |
| CN109091484B (zh) * | 2018-08-15 | 2020-11-03 | 湖南恒伟药业股份有限公司 | 一种预防和治疗阿尔兹海默症的药物组合物 |
| CN109106738A (zh) * | 2018-09-12 | 2019-01-01 | 沈阳高名医药科技有限公司 | 一种神经酸组合物及其在神经保护中的应用 |
| CN112753765A (zh) * | 2019-11-04 | 2021-05-07 | 内蒙古蒙牛乳业（集团）股份有限公司 | 一种抗氧化剂、抗氧化酸奶及其制备方法 |
| CN111248439A (zh) * | 2020-03-31 | 2020-06-09 | 唯思敦食品(上海)有限公司 | 一种预防和辅助治疗阿尔茨海默症的保健食品及其制备方法 |
| CN114287626A (zh) * | 2022-01-12 | 2022-04-08 | 唯思敦食品(上海)有限公司 | 一种健脑组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106267106A (zh) | 增进记忆改善老年痴呆症患者大脑健康状况的组合物 | |
| JP6873517B2 (ja) | 成年女性、高齢者及び亜健康状態の人々に適用できる健康保持製品組成物 | |
| CN104799146A (zh) | 一种改善亚健康的功能性营养食品组合及其制备方法 | |
| JP2004537577A (ja) | 温血動物のストレス状態の予防用及び治療用の（リゾ）ホスファチジルセリン含有製剤 | |
| CN101773595B (zh) | 清肝明目中药茶 | |
| CN105942498A (zh) | 具有治疗糖尿病作用的功能性营养食品组合及其制备方法 | |
| CN111214642A (zh) | 一种疏通微循环的中药组合物 | |
| CN106937741A (zh) | 一种脱脂亚麻籽粉防癌抗癌健康减肥法及其制备方法 | |
| CN103461585B (zh) | 补气养生中药茶 | |
| CN103749824B (zh) | 一种绞股蓝降糖降压保健茶及其制备方法 | |
| CN107048386A (zh) | 一种性功能调节保健食品 | |
| CN101971988B (zh) | 一种用于对妇女更年期进行治疗的组合物 | |
| CN102008083B (zh) | 一种缓解体力疲劳、祛黄褐斑的保健食品 | |
| CN101284096A (zh) | 羊胎素复方护巢美容胶囊 | |
| KR101511364B1 (ko) | 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물 | |
| CN108813500B (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
| CN106173901A (zh) | 一种中药养生面粉 | |
| CN104256618A (zh) | 一种降血糖的食品、保健品或药物组合物 | |
| CN104825379A (zh) | 减少黑色素沉积的美白焕肤晚霜及其制备方法 | |
| CN105055856B (zh) | 一种治疗心脑血管疾病的茶色素中药组合物及其制备方法和用途 | |
| CN109730174A (zh) | 一种降压降脂茶 | |
| CN103110675A (zh) | 改善营养性贫血软胶囊及其制备方法 | |
| Abbas et al. | Therapeutic comparison of flaxseed and black seed supplementation for treatment of type II diabetic patients: Therapeutic comparison of flaxseed and black seed supplementation | |
| CN109123655A (zh) | 一种具有三高人群代餐调节功能的特医食品及制备方法 | |
| KR101154182B1 (ko) | 방광과체질에 처방되는 변비개선용 천연음료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |